Innoviva, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Innoviva, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Debt due within a year is covered 471.1 times by its yearly operating cash. Higher than almost all Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 34.7 times. Higher than 98% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$111Over the last 3 years, every $100 of reported profit came with $111 of operating cash.
Lower than 76% of Healthcare companies in United States.
Self-Funding Ratio
34.7×Over the last 3 years its own operating cash covered its investment spending (capex) 34.7 times.
Higher than 98% of Healthcare companies in United States.
Cash Locked Ratio
$30For every $100 of sales, $30 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $35 tied up three years earlier.
More money tied up than 65% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
$72Sales grew 24% in 3 years; of every extra $100 of sales, $72 became extra profit.
Higher than 75% of Healthcare companies in United States.
Asset Productivity Ratio
+24% / +33%In 3 years sales changed by +24% while total assets changed by +33%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
471.1×Debt due within a year is covered 471.1 times by its yearly operating cash.
Higher than almost all Healthcare companies in United States.
Cash Cushion Ratio
+20%Cash, after subtracting all debt, equals 20% of its market value (net cash).
Higher than 62% of Healthcare companies in United States.
Tangible Assets Ratio
88%Of every $100 the company owns, $88 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 58% of Healthcare companies in United States.
Tangible Net Worth Ratio
83%Of every $100 of net worth, $83 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 64% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Innoviva, Inc. owes $0.28 for every $1 it owns. Net profit rose 1059% in the year to Dec 2025, and grew 8% a year on average over 3 years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
4.9Investors pay $4.9 for every $1 of Innoviva, Inc.'s yearly profit, lower than 85% of Healthcare companies in United States.
P/B ratio
1.23The share price is 1.23 times Innoviva, Inc.'s book value per share, lower than 74% of Healthcare companies in United States.
Market cap
$1.5 BThe total market value of all of Innoviva, Inc.'s shares at today's price (share price × number of shares), larger than 69% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$1.2 BWhat Innoviva, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$17.07Net worth divided by the number of shares. The share price of $21.06 is 1.2 times this, which is the P/B above.
Return on equity (ROE)
36.7%Innoviva, Inc. earned 36.7% on its shareholders' money over the last year, higher than 95% of Healthcare companies in United States.
Owes vs Owns
0.28×Innoviva, Inc. owes $0.28 for every $1 it owns (low), lower than 63% of Healthcare companies in United States.
Dividend yield
NoneInnoviva, Inc. does not currently pay a dividend.
Revenue growth
+15%Revenue rose 15% in the year to Dec 2025, and grew 7% a year on average over 3 years.
Profit growth
+1059%Net profit rose 1059% in the year to Dec 2025, and grew 8% a year on average over 3 years.
Profit margin
65.9%Innoviva, Inc. keeps $66 of every $100 of revenue as net profit.
Cash quality
0.7×Cash from Innoviva, Inc.'s business was 0.7× its reported profit in the year to Dec 2025 — less cash came in than the profit reported.
Interest cover
9.8×Innoviva, Inc.'s operating profit covered its interest costs 9.8 times in the year to Dec 2025.
Cash vs debt
Net cashInnoviva, Inc. held $298 M more cash than debt (net cash) at Dec 2025.
Questions
What is Innoviva, Inc.'s P/E ratio?
Investors pay $4.9 for every $1 of Innoviva, Inc.'s yearly profit, lower than 85% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Innoviva, Inc.: $1.5 B ÷ $1.2 B (30 Jun 2026) = 1.2.
What is Innoviva, Inc.'s return on equity?
Innoviva, Inc. earned 36.7% on its shareholders' money over the last year, higher than 95% of Healthcare companies in United States.
How much does Innoviva, Inc. owe compared with what it owns?
Innoviva, Inc. owes $0.28 for every $1 it owns (low), lower than 63% of Healthcare companies in United States.
Does Innoviva, Inc. pay a dividend?
No. Innoviva, Inc. does not currently pay a dividend.
Is Innoviva, Inc.'s revenue growing?
Revenue rose 15% in the year to Dec 2025, and grew 7% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.